7467-35-8

Basic information

• Product Name: (1-METHYL-1H-BENZOIMIDAZOL-2-YL)-METHANOL
• Synonyms: 1H-Benzimidazole-2-methanol,1-methyl-(9CI);(1-methyl-1H-benzimidazol-2-yl)methanol(SALTDATA: FREE);(1-methyl-2-benzimidazolyl)methanol;(1-methylbenzimidazol-2-yl)methanol;(1-methyl-1H-benzo[d]imidazol-2-yl)methanol
• CAS NO: 7467-35-8
• Molecular Formula: C₉H₁₀N₂O
• Molecular Weight: 162.19
• Product Categories: BENZIMIDAZOLE
• Mol File: 7467-35-8.mol
• Article Data: 31

Chemical Properties

• Boiling Point: 351.7 °C at 760 mmHg
• Flash Point: 166.5 °C
• Appearance: /
• Density: 1.22 g/cm³
• Vapor Pressure: 1.5E-05mmHg at 25°C
• Refractive Index: 1.622
• Storage Temp.: Sealed in dry,Room Temperature
• CAS DataBase Reference: (1-METHYL-1H-BENZOIMIDAZOL-2-YL)-METHANOL(CAS DataBase Reference)
• NIST Chemistry Reference: (1-METHYL-1H-BENZOIMIDAZOL-2-YL)-METHANOL(7467-35-8)
• EPA Substance Registry System: (1-METHYL-1H-BENZOIMIDAZOL-2-YL)-METHANOL(7467-35-8)

Safety Data

• HazardClass: IRRITANT
• Hazardous Substances Data: 7467-35-8(Hazardous Substances Data)

Usage

Uses

1-Methyl-1H-benzimidazole-2-methanol acts as a reagent in the synthesis, structure-activity relationship, antibacterial and antifungal activities of benzimidazoles. Design, synthesis and computational validation of novel benzimidazole/indole-based PPARα and PPARβ partial agonists.

InChI:InChI=1/C9H10N2O/c1-11-8-5-3-2-4-7(8)10-9(11)6-12/h2-5,12H,6H2,1H3

Upstream product

• 2849-93-6 2-benzimidazolecarboxylic acid 
• 35342-97-3 ethyl 1-methyl-1H-benzo[d]imidazole-2-carboxylate 
• 1865-09-4 ethyl 1H-benzimidazole-2-carboxylate 
• 74-83-9 methyl bromide 
• 4856-97-7 2-(Hydroxymethyl)benzimidazole 
• 79-14-1 glycolic Acid 
• 25148-68-9 N-methylbenzene-1,2-diamine dihydrochloride 
• 95-54-5 1,2-diamino-benzene 
• 1632-83-3 1-Methylbenzimidazole 
• 50-00-0 formaldehyd 
• 64266-27-9 3-(2-Hydroxymethyl-benzoimidazol-1-yl)-propionitrile 
• 449796-13-8 N-acetoxy-2-(acetoxymethyl)benzimidazole 
• 33809-91-5 (1H-benzo[d]imidazol-2-yl)methyl acetate 
• 14484-09-4 (1-methyl-1H-benzo[d]imidazol-2-yl)methyl acetate 

Downstream Products

• 14704-61-1 N-((1-methyl-1H-benzimidazol-2-yl)methyl) aniline 
• 934570-40-8 2-(bromomethyl)-1-methyl-1H-benzo[d]imidazolium bromide 
• 1357162-25-4 C₂₀H₁₈N₂O₃ 
• 1357162-33-4 C₂₀H₁₈N₂O₃ 
• 109029-13-2 4-[(1-methyl-1H-benzimidazol-2-yl)methoxy]aniline 
• 1413429-75-0 diethyl {4-[(1-methyl-1H-benzimidazol-2-yl)methoxy]benzylidene}propanedioate 
• 1413429-76-1 diethyl {4-[(1-methyl-1H-benzimidazol2-yl)methoxy]benzyl}propanedioate 
• 1413429-73-8 methyl 2-bromo-3-{4-[(1-methyl-1H-benzimidazol-2-yl)methoxy]phenyl}propanoate 
• 1413429-74-9 5-{4-[(1-methyl-1H-benzimidazol-2-yl)methoxy]benzylidene}-1,3-thiazolidine-2,4-dione 
• 118001-75-5 4-<(1-methyl-2-1H-benzimidazolyl)methoxy>benzaldehyde 
• 109029-43-8 C₁₅H₁₃N₃O₃ 
• 59871-40-8 2-benzyl-1-methyl-1H-benzo[d]imidazole 
• 101092-40-4 (E)-1-methyl-2-((2-phenylhydrazineylidene)methyl)-1H-benzo[d]imidazole 

Relevant articles and documents

COMPOUNDS AS GLP-1R AGONISTS

The present application provides compounds that may be used as a glucagon-like peptide-1 receptors (GLP-1R) agonist, or stereoisomers, tautomers, or pharmaceutically acceptable salts of any of the foregoing. Also provided are pharmaceutical compositions containing such compounds, or stereoisomers, tautomers, or pharmaceutically acceptable salts of any of the foregoing. Methods of prepare these compounds and compositions and method of using them to treat or present a disease or a condition mediated by GLP-1R.

Design, synthesis, and antitumor activity of novel benzoheterocycle derivatives as inhibitors of vascular endothelial growth factor receptor-2 tyrosine kinase

The vascular endothelial growth factor receptor-2 signaling pathway promotes the formation of new blood vessels, and vascular endothelial growth factor receptor-2 tyrosine kinase exists in both active and inactive conformations. Novel indole–benzimidazole and indole–benzothiazole derivatives joined by different linkers are designed and synthesized as inhibitors of vascular endothelial growth factor receptor-2 tyrosine kinase. All the synthesized compounds were evaluated for their cytotoxicity against four human cancer cell lines (HeLa, HT29, A549, and MDA-MB-435) and human umbilical vein endothelial cell. Meanwhile, the inhibitory activities against vascular endothelial growth factor receptor-2 are estimated in vitro and the binding interactions with dual conformations of vascular endothelial growth factor receptor-2 tyrosine kinase are evaluated by molecular docking. Compounds 5a–c and 14 show inhibitory activity against vascular endothelial growth factor receptor-2 tyrosine kinase and promising cytotoxicity, specifically with IC50 values ranging between 0.1 and 1 μM, which imply broad-spectrum antitumor activity. These results provide a deep insight into potential structural modifications for developing potent vascular endothelial growth factor receptor-2 tyrosine kinase inhibitors.

Cobalt(II) complexes based on (1-methyl-1H-benzo[d]imidazol-2-yl) methanol derivative: synthesis, crystal structure, spectroscopy, DFT calculations, and antioxidant activity

In this paper, we present a combined experimental and computational study of two new cobalt(II) complexes as [Co(Hmbm)2(OAc)2] and [Co(Hmbm)2(H2O)2]Cl2 (Hmbm = (1-methyl-1H-benzo[d]imidazol-2-yl)methanol). Both complexes were characterized by FT-IR and UV–vis spectroscopy, elemental analysis, and single-crystal X-ray crystallography. The molecular geometries, electronic transitions, and vibrational frequencies of the two complexes and the ligand (Hmbm) in the ground state have been calculated using global hybrid (B3LYP) and range-separated hybrid (CAM-B3LYP) density functional. Qualitative description of excited states and charge transfer character of electronic transitions states were carried out by plotting the Natural Transition Orbitals (NTOs) for main states, and were assigned to LMCT. The ligand and its Co(II) complexes have been evaluated for their potential as DPPH radical scavengers.